Baird analyst Eric Coldwell raised the firm’s price target on Quest Diagnostics to $154 from $143 and keeps a Neutral rating on the shares. The analyst raised his estimates following management comments who’s emphasis was on partial capture of incremental tailwinds after reinvestment and inflationary uncertainty.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on DGX:
- Doctors gain confidence in new Alzheimer’s blood tests, Bloomberg reports
- Quest Diagnostics price target raised to $165 from $160 at Mizuho
- Quest Diagnostics partners with Northern Light Health in Maine
- Quest Diagnostics awarded group purchasing agreement by Premier
- Quest Diagnostics Completes Acquisition of Outreach Lab Services Business of Summa Health